Abstract This paper comprehensively compares the Kawasaki disease (KD) guidelines from seven countries/regions, including China, Argentina, Europe, Italy, Japan, Spain, and the United States, as retrieved from the PubMed database. It analyzes the similarities and differences in KD diagnosis and treatment among these guidelines. The results show that all guidelines consistently recommend a single infusion of immunoglobulin at a dosage of 2 g/kg as the first-line treatment for KD, and none advocate for the routine use of methylprednisolone or prednisone as standalone first-line treatment options for KD. However, there are some differences among the guidelines regarding classification, diagnostic criteria, and specific treatment methods for KD. Therefore, it is essential to further strengthen international collaboration in guideline development and conduct multicenter clinical research in the future, aiming to achieve a higher level of expert consensus, thereby promoting the enhancement of KD diagnosis and treatment.
PAN Yan,XIE Li-Jian,JIAO Fu-Yong. Interpretation of similarities and differences in Kawasaki disease guidelines at home and abroad[J]. CJCP, 2025, 27(2): 144-147.
PAN Yan,XIE Li-Jian,JIAO Fu-Yong. Interpretation of similarities and differences in Kawasaki disease guidelines at home and abroad[J]. CJCP, 2025, 27(2): 144-147.
Sociedad Argentina de Pediatría, Sociedad Argentina de Cardiología. Kawasaki disease: interdisciplinary and intersocieties consensus (clinical guidelines). Brief version[J]. Arch Argent Pediatr, 2016, 114(4): 385-390. PMID: 27399018. DOI: 10.5546/aap.2016.385.
Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II: treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks[J]. Ital J Pediatr, 2018, 44(1): 103. PMID: 30157893. PMCID: PMC6116479. DOI: 10.1186/s13052-018-0529-2.
Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I: definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase[J]. Ital J Pediatr, 2018, 44(1): 102. PMID: 30157897. PMCID: PMC6116535. DOI: 10.1186/s13052-018-0536-3.
Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)[J]. Pediatr Int, 2020, 62(10): 1135-1138. PMID: 33001522. DOI: 10.1111/ped.14326.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease: the SHARE initiative[J]. Rheumatology (Oxford), 2019, 58(4): 672-682. PMID: 30535127. DOI: 10.1093/rheumatology/key344.
Barrios Tascón A, Centeno Malfaz F, Rojo Sombrero H, et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease[J]. An Pediatr (Engl Ed), 2018, 89(3): 188.e1-188.e22. PMID: 29778491. DOI: 10.1016/j.anpedi.2018.04.003.
